title: Treatment of maxillary sinus carcinoma: clinical results using the Kitasato modality.
abstract: The conventional therapeutic regimen for maxillary sinus carcinoma consists of dissection of the maxilla, full-dose irradiation and extensive chemotherapy. However, the results obtained with this treatment are often poor. Even when patients recover, their quality of life is significantly reduced as a result of deformity of facial structures and swallowing and articulation dysfunctions. A retrospective analysis of 68 patients with maxillary sinus carcinoma treated with the Kitasato modality between 1975 and 1999 was conducted. All patients underwent pergingival maxillary sinus surgery combined with pre- and postoperative irradiation therapy with standardized total doses of 16 Gy; the postoperative irradiation was given in combination with regional intra-arterial infusion chemotherapy administered via the superficial temporal artery. All visible tumor lesions were removed where possible in order to preserve or facilitate cellular immunity after surgery. The cumulative 5-year survival rates were 85.7% for Stage II patients, 88.1% for Stage III, 76.6% for Stage IVA and 75.% for Stage IVB.
authors.affiliation: Department of Otorhinolaryngology, School of Medicine, Kitasato University, Kanagawa, Japan. yaokazuo@med.kitasato-u.ac.jp
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yao
authors.forename: Hiroomi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Katsuhide
authors.initials: K
authors.lastname: Inagi
authors.forename: Meijin
authors.initials: M
authors.lastname: Nakayama
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Makoshi
authors.forename: Hiromi
authors.initials: H
authors.lastname: Nagai
authors.forename: Makito
authors.initials: M
authors.lastname: Okamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D024221:Antineoplastic Protocols; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006785:Hospitals, University / Q000706:statistics & numerical data*; D006801:Humans; D007564:Japan; D008297:Male; D008444:Maxillary Sinus Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D013517:Otorhinolaryngologic Surgical Procedures; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data*; D010844:Picibanil / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012720:Severity of Illness Index; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D010844:Picibanil; D005472:Fluorouracil